NASDAQ$MAZE
Maze Therapeutics Inc · Q3 2025 earnings
Q3 2025 earnings ·
Briefing
Maze Therapeutics reported Q3 2025, net loss of $30.1M.
For Q3 2025, Maze Therapeutics reported a net loss of $30.1M. Management discusses segment performance, capital allocation, and outlook in the earnings filing.
- Net loss $30.1M.
- Maze Therapeutics highlights liquidity, operations, and near-term priorities.
- Maze Therapeutics highlights liquidity, operations, and near-term priorities.
Headline financials
Revenue & EPS history
Maze Therapeutics Inc · Revenue · Quarterly
$2.5M
Forward guidance
The filing discusses Maze Therapeutics's outlook for upcoming periods, including capital allocation, operating priorities, and market risks disclosed in the quarterly report.
Tailwinds
- Maze Therapeutics cites operational execution and demand trends supporting the outlook.
- Balance sheet and liquidity actions aim to fund growth and returns.
Headwinds
- GAAP profitability remained under pressure in Q3 2025.
- Macro, pricing, and input-cost volatility could pressure margins.
- Segment mix and one-time items may affect quarter-to-quarter comparability.
- Clinical trial timing and R&D spend will drive cash needs before product revenue scales.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 2 quarterly earnings reports · overlaid with Q3 2025
+0.3%
Avg return
Earnings day
+2.4%
Avg return
5 days after
+38.8%
Avg return
30 days after
67%
2 / 3 earnings
Positive
+2.0%
Q2 2025
Best reaction
-2.1%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.9% | +0.4% | -5.6% | |
| Q3 2025 | -2.1% | +6.6% | +37.8% | |
| Q2 2025 | +2.0% | +0.2% | +84.1% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro